PLOSJOURNALS.ORG : plosjournals.org - 51 in TOP 100 MEDICAL SITES. Rating: 95900.

Description: PLoS ONE: an inclusive, peer-reviewed, open access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole World.

Most popular searches: clinical research, trial results, plosjournal.sorg, plosjornals.org, plsjournals.org, public library of science, plsojournals.org, phase II, plojournals.org, plosjounrals.org, plosjourals.org, device, clinical trials, plosjournals.org, medical publishing, plosjournals.og, vaccines, plosjournal.org, plosjouranls.org, plosjournals.rog, disease, science, plosjournalsorg, drugs, lposjournals.org, plosournals.org, open access, plos, plosjurnals.org, posjournals.org, losjournals.org, plojsournals.org, clinical trials database, plosjuornals.org, phase I, plosjounals.org, trials journal, plosjournls.org, clinical trial, devices, plosjournas.org, plosojurnals.org, medical research, open-access, human studies, clinical trials databan, plosjournals.or, plosjournasl.org, phase IV, drug, experimental treatment, vaccine, plosjournals.com, plosjournalso.rg, plosjorunals.org, plosjournlas.org, plosjournals.rg, polsjournals.org, plosjournals.ogr, phase III, clinical trials journal

Facet Biotech rejects Biogen offer as inadequate
Facet Biotech Corp. said Tuesday its board rejected a $14.50 per share proposal from Biogen Idec Inc. as inadequate. (FACT) (BIIB)
feeds.bizjournals.com

Senate Panel to Vote Tuesday on Bill
The Senate Finance Committee will vote next Tuesday on a $829 billion health-care bill, after months of efforts to gain consensus on the massive overhaul.
online.wsj.com

Clarient to Release 2009 Third Quarter Financial Results on Tuesday, November 3rd (GlobeNewswire)
ALISO VIEJO, Calif. -- Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the third quarter ended September 30, 2009 after the stock market closes on Tuesday, November 3rd.
us.rd.yahoo.com

Genoptix: Fundamentals and Shorts Protect Against Long and Short Term Downside Risks
Dave Westenberg submits:It’s rare to find companies where extreme growth is complemented with trading multiples near its competitors. Genoptix (GXDX) is a company with both; and the stock is a great long pick and great for near term trading. GXDX currently trades at ~20X earnings in the ttm and less than 20X going forward based on consensus estimates. This about on par with its closest competitors Bio Reference Laboratories (BRLI), Genzyme (GENZ), Quest Diagnostics (DGX), and Lab Corp (LH) who trade ttm at ~21X, ~29X, ~15X, and~15X respectively. What is anomalous about GXDX is its near triple estimated revenue CAGR over the last four years.Complete Story »
seekingalpha.com

Study Counts Benefits of Cutting Salt
A national program to reduce dietary salt could prevent tens of thousands of heart attacks, strokes and deaths and trim as much as $24 billion from the national health-care tab.
online.wsj.com